IGF1 and early-onset autosomal dominant Alzheimer disease: The neuroprotection by intranasally administered insulin is investigated in numerous studies by various authors in Alzheimer’s disease and other neurodegenerative pathologies, but in brain ischemia and reperfusion, predominantly, the protective effect of intranasally administered IGF-1 (but not of insulin) is studied [44,45,46,47].